Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability.

Abstract

The cannabinoid 1 receptor antagonist rimonabant (SR141716) alters rewarding properties and intake of food and drugs. Additionally, striatal dopamine D2 receptor (DRD2) availability has been implicated in reward function. This study shows that chronic treatment of rats with rimonabant (1.0 and 3.0 mg/kg/day) dose-dependently increased DRD2 availability in the dorsal striatum (14 and 23%) compared with vehicle. High-dose rimonabant also increased DRD2 availability in the ventral striatum (12%) and reduced weight gain. Thus, up-regulation of striatal DRD2 by chronic rimonabant administration may be an underlying mechanism of action and confirms the interactions of the endocannabinoid and dopaminergic systems.

• Authors: Cleo L Crunelle, Elsmarieke van de Giessen, Sybille Schulz, Louk J M J Vanderschuren, Kora de Bruin, Wim van den Brink, Jan Booij
• Journal: Addiction biology (Addict Biol) Vol. 18 Issue 6 Pg. 908-11 (Nov 2013) ISSN: 1369-1600 [Electronic] United States
• PMID: 21955259 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 The Authors, Addiction Biology © 2011 Society for the Study of Addiction.

Chemical References

• Cannabinoid Receptor Antagonists
• Piperidines
• Pyrazoles
• Receptors, Dopamine D2
• Rimonabant

Topics

• Animals
• Basal Ganglia (drug effects, metabolism)
• Cannabinoid Receptor Antagonists (pharmacology)
• Dose-Response Relationship, Drug
• Male
• Piperidines (pharmacology)
• Pyrazoles (pharmacology)
• Random Allocation
• Rats
• Receptors, Dopamine D2 (metabolism)
• Reward
• Rimonabant
• Up-Regulation (drug effects)
• Weight Gain (drug effects)